Literature DB >> 8981053

Basis of the antiseizure action of phenytoin.

G Tunnicliff1.   

Abstract

1. Phenytoin has been used with much clinical success against all types of epileptiform seizures, except petit mal epilepsy, for over 50 years. Its mechanism of action, however, is still open to interpretation. 2. Several potential targets for phenytoin action have been identified within the central nervous system. These include the Na-K-ATPase, the GABAA receptor complex, ionotropic glutamate receptors, calcium channels and sigma binding sites. 3. To date, though, the best evidence hinges on the inhibition of voltage-sensitive Na+ channels in the plasma membrane of neurons undergoing seizure activity. Quieter nerve cells are far less affected. Moreover, the fact that phenytoin also has important cardiac antiarrhythymic effects and can inhibit Na+ influx into cardiac cells supports the idea that the primary target of phenytoin is, indeed, the Na+ channel.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8981053     DOI: 10.1016/s0306-3623(96)00062-6

Source DB:  PubMed          Journal:  Gen Pharmacol        ISSN: 0306-3623


  18 in total

Review 1.  Phenytoin: 80 years young, from epilepsy to breast cancer, a remarkable molecule with multiple modes of action.

Authors:  Jan M Keppel Hesselink; David J Kopsky
Journal:  J Neurol       Date:  2017-01-12       Impact factor: 4.849

2.  Small-cell lung cancer (human): potentiation of endocytic membrane activity by voltage-gated Na(+) channel expression in vitro.

Authors:  P U Onganer; M B A Djamgoz
Journal:  J Membr Biol       Date:  2005-03       Impact factor: 1.843

Review 3.  Treatment of drug-induced seizures.

Authors:  Hsien-Yi Chen; Timothy E Albertson; Kent R Olson
Journal:  Br J Clin Pharmacol       Date:  2015-09-17       Impact factor: 4.335

4.  Region-specific changes in gene expression in rat brain after chronic treatment with levetiracetam or phenytoin.

Authors:  Bjørnar Hassel; Erik Taubøll; Renee Shaw; Leif Gjerstad; Ray Dingledine
Journal:  Epilepsia       Date:  2010-09       Impact factor: 5.864

Review 5.  Pharmacological neuroprotection for glaucoma.

Authors:  Glyn Chidlow; John P M Wood; Robert J Casson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

6.  Allosteric modulation of sigma-1 receptors elicits anti-seizure activities.

Authors:  Lin Guo; Yanke Chen; Rui Zhao; Guanghui Wang; Eitan Friedman; Ao Zhang; Xuechu Zhen
Journal:  Br J Pharmacol       Date:  2015-06-26       Impact factor: 8.739

7.  A randomized, placebo-controlled proof-of-concept, crossover trial of phenytoin for hydrocortisone-induced declarative memory changes.

Authors:  E Sherwood Brown; Hanzhang Lu; Daren Denniston; Jinsoo Uh; Binu P Thomas; Thomas J Carmody; Richard J Auchus; Ramon Diaz-Arrastia; Carol Tamminga
Journal:  J Affect Disord       Date:  2013-02-28       Impact factor: 4.839

8.  Anticonvulsant effect of BmK IT2, a sodium channel-specific neurotoxin, in rat models of epilepsy.

Authors:  R Zhao; X-Y Zhang; J Yang; C-C Weng; L-L Jiang; J-W Zhang; X-Q Shu; Y-H Ji
Journal:  Br J Pharmacol       Date:  2008-04-21       Impact factor: 8.739

9.  Diphenytoin, riluzole and lidocaine: three sodium channel blockers, with different mechanisms of action, decrease hippocampal epileptiform activity.

Authors:  Lihong Diao; Jennifer L Hellier; Jessica Uskert-Newsom; Philip A Williams; Kevin J Staley; Audrey S Yee
Journal:  Neuropharmacology       Date:  2013-05-21       Impact factor: 5.250

10.  Animal models for the development of new neuropharmacological therapeutics in the status epilepticus.

Authors:  Ed Martín; Ma Pozo
Journal:  Curr Neuropharmacol       Date:  2006-01       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.